2021
Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection
Gupta GK, Perreault S, Seropian SE, Tormey CA, Hendrickson JE. Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection. Transfusion And Apheresis Science 2021, 60: 103069. PMID: 33546988, DOI: 10.1016/j.transci.2021.103069.Peer-Reviewed Original ResearchConceptsPeripheral blood CD34Day 1Blood CD34Autologous peripheral blood stem cell collectionAutologous peripheral blood stem cell mobilizationPeripheral blood stem cell mobilizationPeripheral blood stem cell collectionBlood stem cell mobilizationBlood stem cell collectionDose of plerixaforAddition of plerixaforPercent of casesStem cell collectionStem cell mobilizationQuality improvement projectAdult patientsRepeat dosingPeripheral CD34Multiple myelomaCell mobilizationCollection goalGroup 2Retrospective evaluationGroup 1Patient experience
2016
Autologous Stem Cell Mobilization in the Age of Plerixafor
Cooper DL, Medoff E, Patel N, Baker J, Pratt K, Foss F, Seropian SE, Perreault S, Wu Y. Autologous Stem Cell Mobilization in the Age of Plerixafor. Clinical Lymphoma Myeloma & Leukemia 2016, 16: 411-416. PMID: 27245311, DOI: 10.1016/j.clml.2016.04.007.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntigens, CD34BenzylaminesCyclamsFemaleGraft SurvivalGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHematopoietic Stem CellsHeterocyclic CompoundsHumansLymphomaMaleMiddle AgedMultiple MyelomaTreatment OutcomeWorkflowConceptsStem cell mobilizationCell mobilizationPlerixafor useG-CSFAutologous stem cell transplantationAutologous stem cell mobilizationGranulocyte-colony stimulating factor (G-CSF) mobilizationDose of plerixaforLess platelet transfusionsStem cell transplantationCD34 cells/Treatment of myelomaCells/High-risk factorsEnough stem cellsStem cellsHematologic tolerancePosttransplantation therapyRelapsed lymphomaPlatelet transfusionsCell transplantationRisk factorsFactor mobilizationPatientsPlerixafor
2011
Late Afternoon Dosing of Plerixafor for Stem Cell Mobilization: A Practical Solution
Cooper DL, Pratt K, Baker J, Medoff E, Conkling-Walsh A, Foss F, Snyder E, Yen W, Seropian SE. Late Afternoon Dosing of Plerixafor for Stem Cell Mobilization: A Practical Solution. Clinical Lymphoma Myeloma & Leukemia 2011, 11: 267-272. PMID: 21658654, DOI: 10.1016/j.clml.2011.03.014.Peer-Reviewed Original ResearchConceptsStem cell mobilizationEnough stem cellsMultiple myelomaCell mobilizationG-CSFPrevious mobilizationGranulocyte colony-stimulating factorNon-Hodgkin lymphomaStem cellsG-CSF mobilizationColony-stimulating factorPrevious chemotherapyPrevious therapyMobilization failurePoor mobilizationEvening injectionsCD34 countHigh riskPatientsPlerixaforCell countCost-effective useMyelomaLenalidomideChemotherapy